PVCT — what changed in the latest 10-Q
A section-by-section comparison of PVCT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +9 | −19 | ~10 | 46 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 3 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +1 | 0 | ~2 | 2 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
● Salaries and related expenses for personnel, including stock-based compensation expense;
General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits, and stock-based compensation, for employees engaged in executive and finance functions. General and administrative expenses also include facility-related costs not otherwise included in re…
Comparison of the Three Months Ended March 31, 2026 and March 31, 2025
The following table summarizes research and development expenses for the three months ended March 31, 2026 and 2025.
Research and development expenses were $333,334 for the three months ended March 31, 2026, a decrease of $69,370, or 17.2%, compared to $402,704 for the same period in 2025. The decrease occurred despite the addition of a new drug candidate and was primarily driven by lower clinical trial and resear…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
The Company held its annual meeting of stockholders on June 18, 2025. Stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of De…
General and administrative expenses consist primarily of salaries, stock-based compensation expense, and other related costs for personnel in executive, finance, accounting, business development, legal, information technology and corporate communication functions. Other costs include facility costs …
Comparison of the Three Months Ended September 30, 2025 and September 30, 2024
Research and development expenses were $345,861 for the three months ended September 30, 2025, representing a decrease of $68,126, or 16.5%, compared to $413,987 for the same period in 2024. The decrease was primarily driven by lower clinical trial and research expenses, reflecting reduced costs rel…
The following table summarizes research and development expenses for the three months ended September 30, 2025 and 2024.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-14
In addition, ongoing international conflicts (including military conflicts between Russia and Ukraine and in the Middle East) have created volatility in the global capital markets and may have further global economic consequences, including disruptions of the supply chain. Any such volatility and di…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice